Clinical Trial Update: Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment [Phase 2, Phase 3]

View source ↗

Summary

This document describes a Phase 2/Phase 3 clinical trial evaluating a combination of anlotinib with nab-paclitaxel and S-1 for second-line treatment of advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Anlotinib (anlotinib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Biliary Tract Cancer, Second Line Treatment | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING